**7. References**

[1] Weller RO, Engelhardt B, Phillips MJ. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol 1996; 6(3):275-288.

Immunotherapy for Malignant Gliomas: A Roadmap for the Future 423

[18] Vrabec M, Van Cauter S, Himmelreich U, Van Gool SW, Sunaert S, De Vleeschouwer S

[19] Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JEA, Kuhl J, Demaerel P et al.

[20] Masucci GV, Mansson-Brahme E, Ragnarsson-Olding B, Nilsson B, Wagenius G,

[21] Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and

[22] van der Most RG, Currie A, Robinson BW, Lake RA. Cranking the immunologic engine

[24] De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J et

[26] Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Reengineering dendritic cell-based

[27] Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G et al. Integration of

[28] Jian B, Yang I, Parsa AT. Monitoring immune responses after glioma vaccine

[29] Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and

[30] Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF et al. Stem cell-

anti-cancer vaccines. Immunol Rev 2008; 222:256-76.:256-276.

immunotherapy. Neurosurg Clin N Am 2010; 21(1):195-199.

outlook. Semin Cancer Biol 2006; 16(1):80-88.

J Clin Oncol 2008; %20;26(18):3015-3024.

towards useful antitumor immunity. Cancer Res 2006; 66(2):601-604. [23] Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A et al. A clinical

et al. MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study.

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with

Hansson J. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. Melanoma Res 2006; 16(4):357-

immunotherapy in the treatment of established murine solid tumors. Cancer Res

with chemotherapy: using context to drive tumor antigen cross-presentation

development paradigm for cancer vaccines and related biologics. J Immunother

al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008; 14(10): 3098-3104. [25] McIlroy D, Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy:

maturation state does have clinical impact. Cancer Immunol Immunother 2003;

autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J

related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in

Cancer 2008; 113(2):405-410.

Br J Cancer 2004; 91:1656-1662.

relapsed malignant glioma, a feasibility study.

Neuroradiology 2010.

2003; 63(15):4490-4496.

2007; 30(1):1-15.

52(10):583-591.

Neurooncol 2010.

glioblastoma.

363.


Cancer 2008; 113(2):405-410.

422 Advances in the Biology, Imaging and Therapies for Glioblastoma

[2] De Vleeschouwer S, Van Gool SW, Van Calenbergh F. Immunotherapy for malignant

[3] Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev

[4] Steinman RM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no

[5] De Vleeschouwer S, Arredouani M, Ade M, Cadot P, Vermassen E, Ceuppens JL et al.

[7] Kalinski P, Hilkens CMU, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and

[8] Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R. Dendritic cell-

[9] Maes W, Galicia Rosas G, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL et al.

[10] Maes W, Van Gool SW. Experimental immunotherapy for malignant glioma: lessons

[11] Mocellin S, Rossi CR, Lise M, Marincola FM. Adjuvant immunotherapy for solid

[12] Dunn GP, Dunn IF, Curry WT. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 2007; 7:12. [13] Van Gool SW, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S. Dendritic cell therapy of high grade gliomas. Brain Pathol 2009; 19:694-712. [14] Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New

[15] Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II

[16] De Vleeschouwer S, Rapp M, Sorg RV, Steiger HJ, Stummer W, Van Gool S et al.

[17] Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA et al.

derived dendritic cells. Cancer Immunol Immunother 2005; 54:372-382.

[6] Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117(5):1195-1203.

experimental glioma. Neuro-oncol 2009; 11(5):529-542.

studies of supratentorial malignant glioma.

future directions. Neurosurgery 2006; 59(5):988-999.

treated with chemoirradiation with temozolomide.

J Clin Oncol 1990; 8(7):1277-1280.

dendritic cells. Childs Nerv Syst 2005; 21:7-18.

Immunol 1991; 9:271-296.

20:561-567.

2009; 5(3):379-390.

2011; 60(2):153-160.

51(11-12):583-595.

92(3):205-16.

more. Science 2004; 305:197-200.

gliomas: emphasis on strategies of active specific immunotherapy using autologous

Uptake and presentation of malignant glioma tumor cell lysates by monocyte-

type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999;

based therapeutic cancer vaccines: what we have and what we need. Future Oncol

DC vaccination with anti-CD25 treatment leads to long-term immunity against

from two decades of research in the GL261 model. Cancer Immunol Immunother

tumors: from promise to clinical application. Cancer Immunol Immunother 2002;

guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;

Dendritic cell vaccination in patients with malignant gliomas: current status and

Incidence of early pseudo-progression in a cohort of malignant glioma patients


J Clin Oncol 2008; %20;26(18):3015-3024.

[31] Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011; 17(6):1603-1615.

[31] Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH et al. Gene expression

17(6):1603-1615.

profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011;
